A Multi-Concept Theme for Digital Agencies and Startups
Ministry of Health and Family Welfare has issued a directive to ban the manufacture, sale, and distribution of the fixed dose combination drug Amylase + Protease + Glucoamylase + Pectinase + Alpha Galactosidase + Lactase + Beta-Gluconase + Cellulase + Lipase + Bromelain + Xylanase + Hemicellulase + Malt diastase + Invertase + Papain, Antimony Potassium Tartrate + Dried Ferrous Sulphate, Benfotiamine + Silymarin + L-Ornithine L-aspartate + Sodium Selenite + Folic acid + Pyridoxine hydrochloride, Bismuth Ammonium Citrate + Papain, Cyproheptadine HCl + Thiamine HCl + Riboflavine + Pyridoxine HCl + Niacinamide, Cyproheptadine Hydrochloride + Tricholine Citrate + Thiamine Hydrochloride + Riboflavine + Pyridoxine Hydrochloride, Rabeprazole Sodium (As enteric coated tablet) + Clidinium Bromide + Dicyclomine HCl + Chlordiazepoxide, Fungal Diastase + Papain + Nux vomica Tincture + Cardamom Tincture + Casein Hydrolysed + Alcohol, Mefenamic Acid + Paracetamol Injection, Omeprazole Magnesium + Dicyclomine HCl, S-adenosyl methionine + Metadoxine + Ursodeoxycholicacid BP + L-Methylfolate Calcium eq. to L-Methylfolate + Choline bitartratee + Silymarin + L-ornithine L-aspartate + Inositol + Taurine, Silymarin + Thiamine Mononitrate + Riboflavin+ Pyridoxine HCl + Niacinamide + Calcium pantothenate + Vitamin B12, Silymarin + Pyridoxine HCl + Cyanocobalamin + Niacinamide + Folic Acid, Silymarin + Vitamin B6 + Vitamin B12 + Niacinamide + Folic acid + Tricholine Citrate for human use. By virtue of the circular, this action is based on recommendations from the Drugs Technical Advisory Board and the powers granted under section 26A of the Drugs and Cosmetics Act, 1940. The drug is deemed to have no therapeutic benefit and may pose risks to human health. Please refer to the attached document for more details.
Request a Demo
CDSL has reiterated the SEBI Circular on the norms for sharing and usage of price data for educational purposes, effective from July 01, 202
CDSL has issued a communique on the incorporation of Lock-In of Pre-Issue Capital during Initial Public Offering. Through this communique,
CDSL has reiterated the SEBI circular on the Fast-Track Mechanism for Processing of Placement Memorandum of AIFs filed with SEBI (“PaR
CDSL has reiterated the SEBI circular on the operationalisation of Past Risk and Return Verification Agency (“PaRRVAâ€). Key hig
7
I
2
Thank You for your interest in Complinity. Your CV has been forwarded to HR. In case your profile is shortlisted, HR shall contact you.
Thank You for your interest in Complinity. Your CV has been forwarded to HR.